Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia
Key facts
- Where
- Brussels, Gent, Leuven, Liège, and Sint-Lambrechts-Woluwe, BelgiumSee the 5 sites
- Phase
- Phase 2/3
Where in Belgium
- Association Hospitaliere De Bruxelles Hopital Universitaire Des Enfants Reine FabiolaBrussels, BelgiumNo longer taking part
- Universitair Ziekenhuis GentGent, BelgiumNo longer taking part
- UZ LeuvenLeuven, BelgiumNo longer taking part
- Centre Hospitalier Universitaire de LiègeLiège, BelgiumNo longer taking part
- Cliniques Universitaires Saint-LucSint-Lambrechts-Woluwe, BelgiumNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- St. Anna Kinderkrebsforschung
- Trial code
- NCT01949129EU 2024-512657-24-00
- Record updated
- 4 September 2026
- Original description
The ALL SCTped 2012 FORUM is a multinational, multi-centre, controlled, prospective phase III study for the therapy and therapy optimisation for children and adolescents with ALL in complete morphological remission (CR, less than 5% bone marrow blasts, no blasts in cerebrospinal fluid, no other extramedullary leukemia), who have an indication for HSCT with a myeloablative conditioning regimen.Read full original descriptionShow less
The ALL SCTped 2012 FORUM is a multinational, multi-centre, controlled, prospective phase III study for the therapy and therapy optimisation for children and adolescents with ALL in complete morphological remission (CR, less than 5% bone marrow blasts, no blasts in cerebrospinal fluid, no other extramedullary leukemia), who have an indication for HSCT with a myeloablative conditioning regimen.
The stratification of patients in first and following remissions according to the individual transplantation modalities rests upon an indication for allogeneic HSCT and the availability of a suitable donor within the individual transplantation groups.
Inclusion: Patients with ALL (except for patients with B-ALL) who fulfil the following criteria:; age at diagnosis ≤ 18 years. Age at HSCT ≤ 21 years; indication for allogeneic HSCT; complete remission (CR) before HSCT; written consent of the parents (legal guardian) and, if necessary, the minor patient via "Informed Consent Form"; no pregnancy; no secondary malignancy; no previous HSCT; HSCT is performed in a study participating centre.
Exclusion: severe concomitant disease that does not allow treatment according to the protocol at the investigator's discretion (e.g. malformation syndromes, cardiac malformations, metabolic disorders); patients who do not fulfil the inclusion criteria; Non Hodgkin-Lymphoma; the whole protocol or essential parts are declined either by patient himself/herself or the respective legal guardian; no consent is given for saving and propagation of anonymous medical data for study reasons; Karnofsky / Lansky score < 50%; subjects unwilling or unable to comply with the study procedures.